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Inflammation plays an important role
in the development of disturbances in
both glucose metabolism and CVD and is
intimately related to several difficult-to-
measure components of metabolic syn-
drome (5). In our study, concerning
inflammation, IDF criteria did not give
any improvement compared with the
NCEP or WHO criteria. Instead, among
men, the IDF definition tended to be in-
ferior to the other two definitions of the
syndrome. In addition, BMI and HOMA-
IR, components not included in the IDF
and NCEP definitions of metabolic syn-
drome, were closely associated with ele-
vated hs-CRP. If other population studies
confirm our finding about a weaker asso-
ciation between the IDF definition of
metabolic syndrome and CRP levels, es-
pecially among men, the new criteria
should be further considered by includ-
ing hs-CRP or replacing waist circumfer-
ence by BMI given that elevated hs-CRP
levels have been shown to add to the
prognostic information of the NCEP de-
fined metabolic syndrome for cardiovas-
cular events (5).
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Paraneoplastic
Insulin Resistance
Syndrome in
Advanced
Aggressive
Fibromatosis
(Desmoid Tumor)
Treated by Imatinib
Mesylate
A51-year-old woman affected by ad-vanced aggressive fibromatosis ofthe abdomen was admitted to the
hospital because of diabetes associated
with severe insulin resistance. Her medi-
cal history was notable for 1) desmoid tu-
mor of the abdomen at age 26 years,
which had undergone 32 surgical resec-
tions (according to the patient), until the
age of 44 and 2) diabetes at age 45 years
initially treated with oral agents and then
by insulin, with persistent poor glucose
control despite progressively increasing
doses. Afterward, the patient received an
intravenous insulin infusion by an exter-
nal pump through a port-a-cath in the
subclavian vein for severe insulin resis-
tance. Intravenous insulin was discontin-
ued due to sepsis, which resolved after
intravenous antibiotic therapy. Family
history was negative for diabetes. Physical
examination revealed poor general condi-
tions and a large mesogastric lesion (Fig.
1A), and BMI was 29.2 kg/m2 and blood
pressure was 140/80 mmHg. Laboratory
investigations were normal, apart from
features of nonketotic insulin-resistant di-
abetes with HbA1c 14.2%, 24-h blood
glucose 300–500 mg/dl, fasting insulin
144 U/ml, proinsulin 45 pmol/l, and C-
peptide 2.88 ng/ml. Autoantibodies to in-
sulin receptor and insulin were absent,
and tumor necrosis factor- (12.5 pg/ml)
and interleukin-6 (11.6 pg/ml) were ele-
vated. Intravenous insulin (1,200 units/
day) had to be resumed. The extreme
insulin resistance in the absence of insulin
receptor antibodies was suggestive of a
paraneoplastic origin. Surgical interven-
tion was unfeasible due to tumor diffu-
sion and impossibility to reconstruct the
abdominal wall. Immunocytochemistry
on the desmoid tumor biopsies revealed
the presence of - and -platelet–derived
growth factor (PDGF) receptors.
In view of the impracticability of
maintaining long-term intravenous insu-
lin, therapy with imatinib mesylate
(Gleevec) was considered (1–3). After ob-
taining ethical committee permission and
patient’s informed consent, imatinib was
started at the dose of 400 mg/day orally.
Insulin requirement dropped dramati-
cally to 500 units/day s.c. within 3 days
and then progressively to a nadir of 100
units/day after 2 months, accompanied by
a significant decrease of tumor mass and
improvement of general clinical condi-
tions and diabetes control. After 6 months
of treatment with imatinib and while still
on treatment with it, partial reenlarge-
ment of the lesion and insulin resistance
slowly recurred with insulin requirement
increasing up to 600 units/day after 8
months of imatinib treatment (Fig. 1B–
G). At that point, leukopenia and anemia
occurred and imatinib had to be discon-
tinued for this reason, with further wors-
ening of severe insulin-resistant diabetes.
We hypothesize that imatinib acted
positively by blocking the negative intra-
cellular cross-talk between PDGF, tumor
necrosis factor-, interleukin-6, and in-
sulin, either by a direct inhibition of the
PDGF tyrosine kinase or by reducing the
tumor mass and the related production of
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interleukin-6, tumor necrosis factor-,
and PDGF (3–5).
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Figure 1—The clinical andmetabolic response of the patient to imatinib therapy.A: The desmoid tumor is a large mesogastric easily bleeding lesion.
B–F: The lesion was measured at admission and after 2, 4, 6, and 8 months of imatinib therapy, demonstrating progressive reduction in the external
size of the tumor with a partial recurrence at 8 months. Daily insulin requirements (G) and HbA1c levels (H) demonstrate a clear-cut positive effect
of the therapy with the tyrosine kinase inhibitor.
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COMMENTS AND
RESPONSES
Proinflammatory
Cytokines, Insulin
Resistance, and
Insulin Secretion in
Chronic Hepatitis C
Patients: A Case-
Control Study
Response to Lecube et al.
W e read with interest the article byLecube et al. (1), which indi-cated that tumor necrosis factor
(TNF)- is a mechanism by which hepa-
titis C virus (HCV)-infected patients are
more prone to develop type 2 diabetes
than patients with other chronic liver dis-
eases. The mechanisms of the develop-
ment of insulin resistance in patients with
chronic HCV infection are not well un-
derstood. Insulin resistance in HCV-
infected patients occurs already at an
early stage in the course of HCV infection
(2). Furthermore, although steatosis was
more severe in patients infected with ge-
notype 3, insulin resistance was associ-
ated with steatosis only in patients
infected with genotype 1 (3).
Recently, we investigated the role of
adipocytokines in HCV-related steatosis
(4). Seventy-one chronic HCV patients
were studied to assess the effects of adi-
pocytokines on steatosis. We used an en-
zyme-linked immunosorbent assay to
determine serum TNF receptors (TNF-R)
I and II concentrations. Based on the find-
ings in the study by Lecube et al. (1), we
investigated whether plasma TNF-RI and
TNF-RII concentrations were associated
with parameters of insulin resistance in
the 68 noncirrhotic subjects of this group
of patients. Genotype distributions were
as follows: genotype non-3, n  55; ge-
notype 3, n  13.
TNF-RII and TNF-RI concentrations
were correlated with homeostasis model
assessment (r  0.26, P  0.02 and r 
0.20, P 0.09, respectively). Homeosta-
sis model assessment was significantly
different in patients with genotype 3 than
in patients with genotype non-3 (1.13 vs.
2.46; P 0.01). There were no significant
differences between the two groups for
age, BMI, TNF-RI, and TNF-RII concen-
trations (genotype 3 versus non-3: TNF-
RI 1.64 vs 1.48 pg/ml, P 0.32; TNF-
RII  3.79 vs. 3.41 pg/ml, P  0.39).
Our results suggest that the HCV ge-
notype must be included in further study
evaluating insulin resistance in HCV-
infected patients. Moreover, the lack of
difference of TNF-R concentrations be-
tween subjects with HCV genotype 3 and
non-3, despite a significant difference for
homeostasis model assessment level, sug-
gests that factors other than TNF- could
be implicated in the development of insu-
lin resistance during HCV chronic
infection.
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Proinflammatory
Cytokines, Insulin
Resistance, and
Insulin Secretion in
Chronic Hepatitis C
Patients: A Case-
Control Study
Response to Petit et al.
W e thank Petit et al. (1) for theirinterest in our study, in whichwe suggest that insulin resistance
mediated by proinflammatory cytokines,
but not a deficit of insulin secretion, is the
primary pathogenic mechanism impli-
cated in the development of diabetes as-
sociated with hepatitis C virus (HCV)
infection (2). Based on the results of our
study, these authors measured tumor ne-
crosis factor (TNF)-soluble receptors
(TNF-RI and TNF-RII) and homeostasis
model assessment (HOMA) in 68 noncir-
rhotic subjects with chronic hepatitis C.
They found that HOMA was significantly
lower in patients with genotype 3 (n 
13) than in patients with genotype non-3
(n  55), and there were no significant
differences between the two groups re-
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